Table 2: Effect of saponarin and silymarin pretreatment on hepatic liver peroxidation and antioxidant profile in rats challenged with paracetamol.

GroupMDAaGSHa SODbCATcGPxbGRbGSTd

Control0.655 ± 0.055.52 ± 0.630.169 ± 0.018121.0 ± 7.80.131 ± 0.0160.222 ± 0.0280.233 ± 0.03
PC0.854 ± 0.04*0.96 ± 0.05**0.114 ± 0.012*88.3 ± 10*0.089 ± 0.01*0.137 ± 0.02*0.160 ± 0.01*
SP0.635 ± 0.075.14 ± 0.310.158 ± 0.015110.4 ± 160.125 ± 0.020.207 ± 0.030.208 ± 0.02
PC + SP0.704 ± 0.02+1.23 ± 0.15*+0.141 ± 0.02*+94.6 ± 7.80.108 ± 0.0150.191 ± 0.02+0.194 ± 0.02+
SL0.673 ± 0.075.01 ± 0.640.162 ± 0.024137.6 ± 130.144 ± 0.020.200 ± 0.090.245 ± 0.03
PC + SL0.690 ± 0.06+1.40 ± 0.12*+0.138 ± 0.02*+108.1 ± 7+0.113 ± 0.01+0.199 ± 0.02+0.149 ± 0.03*

Treatment: paracetamol administered at a dose of 600 mg/kg i.p., alone (PC group) and two hours after the last administration of the hepatoprotective agents (SP + PC and SL + PC groups); saponarin (SP) (80 mg/kg bw/day) and silymarin (SL) (100 mg/kg bw/day were administered p.o. for 7 days. Data are expressed as mean ± SEM of six rats. *Significant difference from control values (Mann-Whitney U test, ). +Significant difference from paracetamol-treated group (Mann- Whitney U test, ).
anmol/g protein.
bnmol/min/mg protein.
cμmol H2O2/min/mg protein.
dnmol CDNB-GSH conjugate formed/min/mg protein.